| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Genomic Vision S.A. (LSE: 0QT4)
0QT4 Technical Analysis
5
| As on 22nd Mar 2022 0QT4 STOCK Price closed @ 0.14 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.34 & Strong Sell for SHORT-TERM with Stoploss of 0.72 we also expect STOCK to react on Following IMPORTANT LEVELS. |
0QT4STOCK Price
| Open | 0.14 | Change | Price | % |
| High | 0.14 | 1 Day | -0.02 | -12.50 |
| Low | 0.14 | 1 Week | -0.10 | -41.67 |
| Close | 0.14 | 1 Month | -0.16 | -53.33 |
| Volume | 11473 | 1 Year | -0.56 | -80.00 |
| 52 Week High 1.24 | 52 Week Low 0.14 | ||||
LSE UK Most Active Stocks
| DKE | 0.15 | 0.00% |
| NNN | 0.09 | 50.00% |
| SYME | 0.10 | -9.09% |
| DMTR | 0.03 | 0.00% |
| PREM | 0.53 | 3.92% |
| MCLS | 1.68 | 46.09% |
| YGEN | 0.49 | 0.00% |
| CLON | 0.11 | 0.00% |
| VOD | 71.04 | 0.57% |
| BOIL | 0.10 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| 0QT4 Daily Charts |
0QT4 Intraday Charts |
Whats New @ Bazaartrend |
0QT4 Free Analysis |
|
|
0QT4 Important Levels Intraday
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.14 |
0QT4 Forecast May 2024
| 4th UP Forecast | 1.03 |
| 3rd UP Forecast | 0.74 |
| 2nd UP Forecast | 0.57 |
| 1st UP Forecast | 0.39 |
| 1st DOWN Forecast | -0.11 |
| 2nd DOWN Forecast | -0.29 |
| 3rd DOWN Forecast | -0.46 |
| 4th DOWN Forecast | -0.75 |
0QT4 Weekly Forecast
| 4th UP Forecast | 1.12 |
| 3rd UP Forecast | 0.81 |
| 2nd UP Forecast | 0.61 |
| 1st UP Forecast | 0.42 |
| 1st DOWN Forecast | -0.14 |
| 2nd DOWN Forecast | -0.33 |
| 3rd DOWN Forecast | -0.53 |
| 4th DOWN Forecast | -0.84 |
0QT4 Forecast2024
| 4th UP Forecast | 2.34 |
| 3rd UP Forecast | 1.63 |
| 2nd UP Forecast | 1.2 |
| 1st UP Forecast | 0.76 |
| 1st DOWN Forecast | -0.48 |
| 2nd DOWN Forecast | -0.92 |
| 3rd DOWN Forecast | -1.35 |
| 4th DOWN Forecast | -2.06 |
Genomic Vision S.A. ( LSE UK Symbol : 0QT4 )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
0QT4 Business Profile
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides CombHeliX FSHD probes for the diagnosis of facioscapulohumeral dystrophy; FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur; and development agreement with Integrated Technologies Ltd for the design and development of a high-throughput scanning instrument for molecular combing assays. The company was founded in 2004 and is headquartered in Bagneux, France. Address: Green Square Batiment E, Bagneux, France, 92220
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service